Back

Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM

30 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New insights into cardiac amyloidosis Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Emer Joyce

Mater Misericordiae University Hospital, Dublin (Ireland)

6 More presentations in this session

Presentation thumbnail
Decoding peripartum cardiomyopathy through multi-omics: circulating and cellular signatures from the Italian multicenter registry
Doctor M. Carotenuto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Vascular dysfunction is associated with symptom severity and quality of life in wild-type transthyretin amyloid cardiomyopathy
Mr N. Ogasawara (Akita, JP)
Abstract Slides Video
Presentation thumbnail
Diagnostic utility of three clinical scoring systems for transthyretin amyloid cardiomyopathy in elderly Asian patients with heart failure with preserved ejection fraction
Doctor M. Chen (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
Doctor N. Sarswat (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Which therapy performs best across clinical domains in transthyretin amyloid cardiomyopathy? a frequentist network meta-analysis
Mr A. Calderon Fernandez (Tijuana, MX)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
18 May 2025
thumbnail
Congress Presentation
Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy
29 August 2025
thumbnail
Congress Presentation
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
31 August 2026
thumbnail
Congress Presentation
Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources